Clinical Trials Sponsored by Blueprint Medicines Corporation

Total 159 results

Blueprint Medicines Corporation

Recruiting

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor | Solid Tumor, Unspecified, Child | Relapsed Solid Neoplasm

United States, Korea, Republic of, United Kingdom, France, Canada, Australia, Austria, Germany, Italy
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
Blueprint Medicines Corporation

Active, not recruiting

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

Canada, United States, Spain, United Kingdom, Germany, Belgium, Switzerland, Italy, Netherlands, Denmark, France, Norway, Sweden
Blueprint Medicines Corporation

Completed

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Relapsed or Refractory Myeloid Malignancies

United States, United Kingdom
Blueprint Medicines Corporation

Completed

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST

United States, Korea, Republic of, Netherlands, China, France, Spain, Italy, Belgium, United Kingdom, Singapore, Australia, Canada, Germany, Sweden, Hungary, Austria, Czechia, Poland
Blueprint Medicines Corporation

Completed

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

Gastrointestinal Stromal Tumors (GIST) | Other Relapsed or Refractory Solid Tumors

United States, United Kingdom, France, Korea, Republic of, Belgium, Germany, Italy, Netherlands, Poland, Spain
Blueprint Medicines Corporation

Approved for marketing

Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC

Non-Small Cell Lung Cancer | Medullary Thyroid Cancer
Blueprint Medicines Corporation

Recruiting

(VELA) Study of BLU-222 in Advanced Solid Tumors

Gastric Cancer | Ovarian Cancer | Carcinosarcoma | Advanced Solid Tumors | Endometrial Cancer | Esophageal Adenocarcinoma | HER2-negative Breast Cancer | CCNE1 Amplification | HR+ Breast Cancer

United States, Italy, United Kingdom
Blueprint Medicines Corporation

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis | Monoclonal Mast Cell Activation Syndrome

United States, Spain, Australia, France, Netherlands, Switzerland, Norway, United Kingdom, Austria, Belgium, Germany, Italy, Portugal
Blueprint Medicines Corporation

Completed

A Drug-drug Interaction Study of Avapritinib and Midazolam

Gastrointestinal Stromal Tumors | GIST | Non-resectable Advanced Solid Tumors | Recurrent or Unresectable Central Nervous System (CNS) Tumors

United States
Blueprint Medicines Corporation

Available

Expanded Access Program for Avapritinib

Solid Tumors
Blueprint Medicines Corporation

Active, not recruiting

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
Blueprint Medicines Corporation

Active, not recruiting

Study for Patients Previously Treated in Avapritinib Clinical Trials

Gastrointestinal Stromal Tumors

France
Blueprint Medicines Corporation

Approved for marketing

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST
Blueprint Medicines Corporation

Recruiting

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)

Advanced Systemic Mastocytosis

United States, Norway, Netherlands, Belgium, Germany, France, Spain
Blueprint Medicines Corporation

Completed

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China, Korea, Republic of, Taiwan, Hong Kong, United Kingdom, United States, France, Spain, Switzerland, Singapore, Germany, Italy
Blueprint Medicines Corporation

Active, not recruiting

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Blueprint Medicines Corporation

Completed

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Systemic Mast Cell Activation | KIT D816V Mutation

United States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland
Blueprint Medicines Corporation

Completed

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

Healthy Volunteers

United States
Blueprint Medicines Corporation
PatientCrossroads

Completed

Mast Cell Connect: A Registry for Patients With Mastocytosis

Mastocytosis

United States
Genentech, Inc.
Blueprint Medicines Corporation

Recruiting

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Centre Leon Berard
Blueprint Medicines Corporation

Active, not recruiting

French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients (AVIATOR2020)

GIST, Malignant | GIST | PDGFR-Alpha D842V

France
Blueprint Medicines Corporation
Analysis Group, Inc.

Completed

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological Neoplasm

United States, Austria, Germany, Spain, United Kingdom
Adelphi Values LLC
Blueprint Medicines Corporation

Completed

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

Mast Cell Leukemia (MCL) | Aggressive Systemic Mastocytosis (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Smoldering Systemic Mastocytosis (SSM) | Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited

United States
Blueprint Medicines Corporation
Analysis Group, Inc.

Enrolling by invitation

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms... and other conditions

United States, France, Switzerland
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation

Recruiting

Avapritinib With Decitabine in Patients With SM-AHN

Systemic Mastocytosis With an Associated Hematologic Neoplasm

United States
Frontier Medicines Corporation

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C Mutations

United States
Link Medicine Corporation

Completed

A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers

Healthy Elderly Volunteers

United States
Link Medicine Corporation

Completed

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

Mild Alzheimer's Disease

United States
Medicis Pharmaceutical Corporation

Completed

A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.

Human Volunteer

United States
Medicis Technologies Corporation

Completed

Subcutaneous Contouring Using High Intensity Focused Ultrasound

Body Sculpting

Canada
Hamad Medical Corporation
Sidra Medicine

Unknown

Hybrid Closed Loop System for Patients on Multiple Daily Insulin Injections

Type 1 Diabetes

Qatar
DBYAN Medicine Professional Corporation
Allergan

Completed

A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt (CICOM1010)

Ocular Hypertension | Open Angle Glaucoma

Canada
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Medicis Global Service Corporation

Unknown

Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit

Facial Volume

United States
Medicis Global Service Corporation

Completed

Combination Treatment for Moderate to Severe Acne

Acne

United States
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Cruris

Tinea Cruris

United States, Puerto Rico, Honduras, El Salvador, Belize
Medicis Global Service Corporation

Completed

Topical Antifungal Treatment for Tinea Pedis

Tinea Pedis

United States, Belize
Medicis Global Service Corporation

Completed

Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles

Peri-oral Wrinkles

United States
Medicis Global Service Corporation

Completed

Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

Seborrheic Dermatitis

United States
Medicis Global Service Corporation

Completed

Safety/Efficacy Study of Restylane® in Lip Augmentation

Lip Augmentation

United States
Medicis Global Service Corporation

Completed

Safety and Efficacy Study to Treat Bacterial Vaginosis

Bacterial Vaginosis

United States
Medicis Global Service Corporation

Unknown

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

Actinic Keratosis

United States
Baylor College of Medicine
CONMED Corporation

Completed

ConMed Beamer Study

Gastrointestinal Neoplasms | Gastroparesis | Achalasia

United States
Banff Sport Medicine Foundation
CONMED Corporation

Not yet recruiting

Biologic Augment of the Medial Patellofemoral Ligament Following Primary Lateral Patellofemoral Dislocation (BioPPD) (BioPPD)

Patellofemoral Dislocation
Baylor College of Medicine
Thoratec Corporation

Completed

The IMPULSE Study: Pilot (IMPULSE)

Chronic Heart Failure

United States
Northwestern University
Medicis Pharmaceutical Corporation

Completed

Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone

Forehead/Glabellar Rhytid Complexes

United States

Clinical Trials Sponsored by Blueprint Medicines Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations